ClinicalTrials.gov
--------------------

ClinicalTrials.gov is a service of the National Institutes of Health

## More details available in the Expanded Access Data Element Definitions

## **Expanded Access Protocol Registration Template**

For more information, see How to Register Your Study at https://clinicaltrials.gov/ct2/manage-recs/how-register.

<ul> <li>* Required</li> <li>*§ Required if Study Start Date is on or after January 18, 2017</li> <li>[*] Conditionally Required</li> </ul>									
1. STUDY IDENTIFICATION									
*Unique Protocol Identification Number:	*Brief Title:								
[*]Official Title (Optional if Expanded Access Type is "Individual Patients"): [*]Acronym (if any):									
*Study Type (select one): O Interventional	Observational Observa	ational—Patient Registry	Expanded Access						
i If Expanded Access does not involve a U.S. FDA-regu	lated drug product, select "Not Applicable".								
*§Expanded Access Type (select all that a	apply): 🗌 Not Applicable 📃 Ind	ividual Patients	nediate-size Population	atment IND/Protocol					
i More than one Secondary ID can be entered. If more the	han two are needed, more space is available in	the PRS.							
[*]Secondary ID 1 (if any) (Optional if Exp	panded Access Type is "Individu	al Patients"):							
[*]Secondary ID 1 Type (select one): U.S. National Institutes of Health (NIH) Grant/Contract Award Number Other Grant/Funding Number Registry Identifier									
i If "Other Grant/Funding Number", "Registry Identifier",	or "Other Identifier" is selected for Secondary ID	) Type, provide the name of the fun	ding organization, trial registry, or organiz	ation that issued the ID.					
<ul> <li>[*]Description 1:</li> <li>[*]Secondary ID 2 (if any) (Optional if Explanation of the explanation o</li></ul>	panded Access Type is "Individu	val Patients"):							
[*]Secondary ID 2 Type (select one):	Other Grant/Funding Number Other Identifier	Registry Identifier							
If "Other Grant/Funding Number", "Registry Identifier",	or "Other Identifier" is selected for Secondary IE	) Type, provide the name of the fun	ding organization, trial registry, or organiz	ation that issued the ID.					
[*]Description 2:									
	2. STUE	DY STATUS							
*Record Verification Date: Month:		Year:							
*Expanded Access Status (select one):	Available No longer available	e O Temporarily not availa	able O Approved for marketing						
	3. SPONSORS/	COLLABORATORS							
*Responsible Party, by Official Title (sele	ct one): Osponsor OPrincipa	al Investigator O Sponso	or-Investigator						
Investigator Information is required only for "Principal Investigator" or "Sponsor-Investigator."									
[*]Investigator Information:									
Investigator Name:									
Investigator Official Title:		Investigator Affiliation:							

3. SPONSORS/COLLABORATORS (CONTINUED)											
*Name of the Sponsor											
Enter as many Collaborators as needed. Additional fields are available in the PRS.											
	Collaborators (if any):										
Name of Colla	lame of Collaborator 1: Name of Collaborator 2:										
4. OVERSIGHT											
*U.S. Food and Drug Administration IND or IDE (select one):											
If Yes, provide information below:											
[*]FDA Center	(select one): OCDER		[*]IND/	/IDE Nur	mber:	[*]IND Serial Numb	er:				
			E OTU		RIPTION						
*Drief Summer			5. 510	DT DESC							
Bilei Sullilla	y (using lay language):										
Detailed Desc	ription.										
Bolanda Boool											
			. CONDITIC	ONS AND	KEYWORDS						
Enter as many	Conditions as needed. Additional fields are a	vailable in the PRS.									
[*]Conditions of	or Focus of Study (Optional if E	Expanded Acce	ss Type is	"Individ	ual Patients"):						
1.					,						
2.											
i Enter as many	Keywords as needed. Additional fields are av	ailable in the PRS.									
Keywords:											
1.											
2.											
			7. IN	TERVEN	TIONS						
Enter as many l	nterventions as needed. Additional fields are	available in the PRS.									
Intervention 1:	*Intervention Type (select one):	Drug	Device		Biological/Vaccine	Procedure/Surgery	Radiation	Behavioral			
		Genetic	Dietary Su	pplement	Combination Product	Diagnostic Test	Other				
*Intervention N	lame:										
[*]Other Interv	ention Name 1 (if any) (Option	al if Expanded	Access	[*10the	r Intervention Name 3	2 (if any) (Ontional	if Expanded	Access			
[*]Other Intervention Name 1 (if any) (Optional if Expanded Access         Type is "Individual Patients"):             [*]Other Intervention Name 2 (if any) (Optional if Expanded Access         Type is "Individual Patients"):											
[*]Intervention Description (Optional if Expanded Access Type is "Individual Patients"):											
		deu Access Ty		nuuaria	duerno j.						
Intervention 2:	*Intervention Type (select one):	Drug	Device		Biological/Vaccine	Procedure/Surgery	Radiation	Behavioral			
		Genetic	Dietary Su	pplement	Combination Product	Diagnostic Test	Other				

7. INTERVENTIONS (CONTINUED)											
*Intervention Name:											
Chother Intervention Name 4 (if any) (Ontion	al if Europealas	1									
[*]Other Intervention Name 1 (if any) (Option Type is "Individual Patients"):	al If Expanded	Access	"Individual Patients"		ptional if Expanded Access Type is						
			/-								
[*]Intervention Description (Optional if Expan	ded Access Ty	ype is "Inc	lividual Patients"):								
8. ELIGIBILITY											
[*]Sex/Gender (Optional if Expanded Access		idual Patie	ents"):								
[*]Sex (select one): All Female	) Male										
[*]Gender Based (if any): Ves	) No										
If Yes, provide descriptive information about the Gender Base	ed criteria.										
Gender Eligibility Description:											
	1		ſ	1							
[*]Age Limits: (Optional if Expanded Access	[*]Minimum	Age:	[*]Unit of Time:	[*]Maximum Age:	[*]Unit of Time:						
Type is "Individual Patients"):											
i Provide bulleted lists (one criterion per bullet) below the head	lers "Inclusion Criteria	a" and "Exclusi	ion Criteria."								
[*]Eligibility Criteria (Optional if Expanded Ac	cess Type is "	Individual	Patients"):								
	9. CONTACTS, I	LOCATION	S, AND INVESTIGATOR								
*Central Contact Person: First Name:			Middle Initial:	*Last Name or Official Title:							
Degree											
Degree:	<b>F</b> .(.)	<b>F</b> 1									
*Phone:	Ext.: *	Email:									
			· · · · · · · · · · · · · · · · · · ·		· · -						
Central Contact Backup: First Name:			Middle Initial:	Last Name or Offic	cial Title:						
Degree:											
Phone:	Ext.: E	mail:									
Enter as many Overall Study Officials as needed. Additional	fields are available in	the PRS.									
Overall Study Official 1: First Name:			Middle Initial:	Last Name:							
Degree:			Organizationa	Organizational Affiliation:							
Official's Role (select one): O Study Chair	) Study Director	Study Pr	incipal Investigator								

9. CONTACTS, LOCATIONS, AND INVESTIGATOR INFORMATION (CONTINUED)										
Overall Study Official 2:		2: First Name:		Middle Initial:		Last Name:				
Degree:			Organizational Affiliation:							
Official's Role (select one): Study Chair Study Director Study Principal Investigator										
*Facility Information:		*§Facility Name: *City:		*City:			State/Province: *§ZIP/Postal Code: *Country:		*Country:	
Facility Contact:		First Name:		Middle Initi	Niddle Initial: Last Name or Official Title:		Official Title:			
·										
Degree:										
Phone:			Ext.:	Email:						
Facility Contact E	Backup:	First Name:		Middle Initial:		Last Name:				
Degree:					1					
Phone:			Ext.:	Email:						
Enter as many Inve	estigators as	needed. Additional fields are a	vailable in the Pl	RS.						
Investigators:		First Name:			Middle Initial:		Last Name:			
Degree:					1					
Role (select one)	): OSite	Principal Investigator	Site Sub-Inve	stigator						
		-	-	10. REFE	RENCES					
		ks items as needed. Additiona	al fields are availa	able in the PRS.						
Citations:	PubMe		Citation:							
-										
Results Reference (select one): Ves ONo										
Links: URL:										
Description:										